ZVSA · ZyVersa Therapeutics, Inc.
$0.10
+0.00 (+0.00%)
At close · Aug 17
Going-concern doubt
— flagged May 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These uncertainties raise substantial doubt about our ability to continue as a going concern for 12 months after the issuance date of our financial statements.”View the 10-Q filed May 13, 2026
Market Cap
$801,496
Shares
8.10M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Stephen C. Glover | Co-Founder, Chief Executive Officer President and Chairman | $993,217 |
| Peter Wolfe | Chief Financial Officer and Secretary | $573,359 |
| Karen A. Cashmere | Chief Commercial Officer | $486,687 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Stephen C. Glover | Co-Founder, Chief Executive Officer President and Chairman | $1,478,448 |
| Karen A. Cashmere | Chief Commercial Officer | $582,622 |
| Peter Wolfe | Chief Financial Officer and Secretary | $557,622 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Min Chul Park, Ph.D. | independent director | Resigned | 2026-07-10 |
| Robert G. Finizio | independent director | Resigned | 2025-12-03 |
| Pablo Guzman, M.D. | Chief Medical Officer and Senior Vice President of Medical Affairs | Resigned | 2025-10-15 |
| Robert G. Finizio | Class III director | Appointed | 2025-06-12 |
| Stephen C. Glover | Class III director | Appointed | 2025-06-12 |
| Min Chul Park, Ph.D. | Class II Director | Appointed | 2024-10-30 |
| Nicholas A. LaBella, Jr. | Chief Scientific Officer and Senior Vice President of Research and Development | Retired | 2023-08-18 |
| Daniel J. O'Connor | Board | Resigned | 2023-05-19 |
| Katrin Rupalla, Ph.D. | Board of Directors | Resigned | 2023-05-19 |
| Katrin Rupalla | member of the board | Appointed | 2023-01-06 |
| Gregory Freitag | member of the board | Appointed | 2023-01-06 |
| James Sapirstein | member of the board | Appointed | 2023-01-06 |
| Karen Cashmere | Chief Commercial Officer | Appointed | 2022-12-13 |
| Nicholas A. LaBella | Chief Scientific Officer | Appointed | 2022-12-13 |
| Peter Wolfe | Chief Financial Officer and Secretary | Appointed | 2022-12-13 |
| Daniel J. O'Connor | directors of the Company | Appointed | 2022-12-13 |
| Stephen C. Glover | President and Chief Executive Officer | Appointed | 2022-12-13 |
| Min-Chul Park | directors of the Company | Appointed | 2022-12-13 |
| Stephen C. Glover | directors of the Company | Appointed | 2022-12-13 |
| Robert Finizio | directors of the Company | Appointed | 2022-12-13 |
| Peter Wolfe | Chief Financial Officer and Secretary | Appointed | 2022-12-13 |
| Karen Cashmere | Chief Commercial Officer | Appointed | 2022-12-13 |
| Nicholas A. LaBella | Chief Scientific Officer | Appointed | 2022-12-13 |
| Min-Chul Park | Director | Appointed | 2022-12-13 |
| Stephen C. Glover | President and Chief Executive Officer | Appointed | 2022-12-13 |